Breast Cancer Research and Treatment

, Volume 67, Issue 3, pp 263–271

Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison

  • Marc Lacroix
  • Gilbert Querton
  • Philippe Hennebert
  • Denis Larsimont
  • Guy Leclercq
Article

Abstract

Estrogen receptor (ER) status is an important parameter in breast cancer management. In this study, ER protein contents established by two conventional techniques were confronted to ER mRNA level, to analyze whether the latter may be introduced in routine assay. Eighty-seven breast tumor samples were examined. ER amounts were determined by ligand-binding assay (LBA) and by computer-assisted immunocytochemical assay (ICA), ER mRNA was analysed and quantified by northern blot. Seventy-seven percent of tumor samples examined were positive for ER mRNA and they all expressed the 6.7-kb receptor signal. No trace of small-sized ER mRNA variants was detected in any sample. Following akaike information criterion (AIC) discriminant analysis, a simple linear correlation was found between ER mRNA levels and ER amounts provided by LBA. This was not observed when either mRNA or LBA values were compared to ICA values. These latter were found to rapidly reach a plateau at increasing mRNA or LBA values. In conclusion, our data points to the linear correlation between ER amounts determined in breast tumors at both protein and mRNA levels by quantitative methods; they also indicate that the semi-quantitative computer-associated ICA may complement rather than replace these quantitative methods.

akaike information criterion (AIC) breast cancer DCC estrogen receptor immunocytochemical assay (ICA) ligand-binding assay mRNA northern-blot 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer (Pred Oncol) 89: 111-117, 2000Google Scholar
  2. 2.
    Blankenstein MA: Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Experience of the E. O. R.T.C. Receptor Group. Breast Cancer Res Treat 17: 91-98, 1990Google Scholar
  3. 3.
    Valavaara R: Reliability of estrogen receptors in predicting response to antiestrogens. Oncology (Huntington) 11: 14-18, 1997Google Scholar
  4. 4.
    Bacus S, Flowers JL, Press MF, Bacus JW, McCarty Jr KS: The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. AmJ Clin Pathol 90: 233-239, 1988Google Scholar
  5. 5.
    Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999Google Scholar
  6. 6.
    Dowsett M, Daffada A, Chan CMW, Johnston SRD: Oestrogen receptor mutants and variants in breast cancer. Eur J Cancer 33: 1177-1183, 1997Google Scholar
  7. 7.
    Lacroix M, Body JJ: Regulation of c-fos and c-jun expression by calcitonin in human breast cancer cells. Calcif Tissue Int 60: 513-519, 1997Google Scholar
  8. 8.
    Lacroix M, Siwek B, Marie PJ, Body JJ: Production and regulation of interleukin-11 by breast cancer cells. Cancer Lett 127: 29-35, 1998Google Scholar
  9. 9.
    Jin L, Borras M, Lacroix M, Legros N, Leclercq G: Antiestrogenic activity of two 11 beta-estradiol derivatives on MCF-7 breast cancer cells. Steroids 60: 512-518, 1995Google Scholar
  10. 10.
    Maaroufi Y, Lacroix M, Lespagnard L, Journé F, Larsimont D, Leclercq G: Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis. Breast Cancer Res 2: 444-454, 2000Google Scholar
  11. 11.
    E.O.R.T.C.: Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C.Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515, 1980Google Scholar
  12. 12.
    Bevitt DJ, Milton ID, Piggot N, Henry L, Carter MJ, Toms GL, Lennard TW, Westley B, Angus B, Horne CH: New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. J Pathol 183: 228-232, 1997Google Scholar
  13. 13.
    Akaike H: A new look at the statistical model identification. IEEE Trans Autom Control AC-19: 716-723, 1974Google Scholar
  14. 14.
    Barrett-Lee PJ, Travers MT, McClelland RA, Luqmani Y, Coombes RC: Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 47: 6653-6659, 1987Google Scholar
  15. 15.
    Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M, Chambon P: Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82: 7889-7893, 1985Google Scholar
  16. 16.
    Weigel RJ, deConinck EC: Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res 53: 3472-3474, 1993Google Scholar
  17. 17.
    Donegan WL: Prognostic factors. Stage and receptor status in breast cancer. Cancer 70: 1755-1764, 1992Google Scholar
  18. 18.
    van Dijk MAJ, Hart AAM, van't Veer LJ: Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas. Cancer Res 60: 530-533, 2000Google Scholar
  19. 19.
    McClelland RA, Berger U, Miller LS, Powles TJ, Coombes R: Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol 4: 1171-1176, 1986Google Scholar
  20. 20.
    Parl FF, Posey YF: Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 19: 960-966, 1988Google Scholar
  21. 21.
    Maaroufi Y, Trivedi S, Leclercq G: Major molecular weight heterogeneity of estrogen receptor from breast cancer is not related to neoplasia. Cancer Biochem Biophys 15: 67-78, 1995Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Marc Lacroix
    • 1
  • Gilbert Querton
    • 2
  • Philippe Hennebert
    • 1
  • Denis Larsimont
    • 2
  • Guy Leclercq
    • 1
  1. 1.Laboratoire Jean-Claude Heuson de Cancérologie MammaireBrussels
  2. 2.Laboratoire d'Anatomie PathologiqueInstitut Jules Bordet, Université Libre de BruxellesBrusselsBelgium

Personalised recommendations